Dr. Jennings brings more than 25 years of biotechnology industry experience spanning global pharma to early stage biotech start-ups. Prior to Liphorus, Dr. Jennings was Director of Computational Sciences and Crystallography at Takeda California where he led the development of novel computational techniques focused on supporting structure based and ligand based drug discovery, and placing
Mr. Dixon has over 16 years of experience working in an executive role for venture-backed companies. Mr. Dixon is a Venture Partner with Sanderling Ventures and the President and CEO of Therillia, a Montreal based operating company with the goal of cost-effectively developing novel drug candidates from preclinical to clinical proof of concept.
Dr. McWilliams is the Chairman and Acting CEO of Liphorus Pharmaceuticals. He is a Managing Director with Sanderling Ventures and has more than twenty years of experience in biomedical research and management. He works actively with Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team.
Dr. Laurence Terrisse Rulleau, Ph.D. is a Principal with CTI Life Sciences, a Montreal-based venture capital fund making investments in pre-clinical and clinical development stage in Canada and in the U.S. Prior to CTI, she served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years.
Dr. Seidah started studying the processing of precursor proteins at the Clinical Research Institute of Montreal (IRCM) in 1974 and, shortly thereafter, co-discovered ß-endorphin and largely contributed to the biochemical characterization of proopiomelanocortin (POMC, the ß-endorphin precursor), discovered and cloned seven (PC1, PC2, PC4, PC5, PC7, SKI-1 and PCSK9) of the nine known enzymes belonging to the proprotein convertase family.